EUVIMEDEUVIMED entdecken
Open Access

HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084

Jessica M Fogel iD, Deborah Persaud, Estelle Piwowar-Manning, Paul Richardson, Joseph Szewczyk, Mark A Marzinke, Zhe Wang, Xu Guo, Marybeth McCauley, Jennifer Farrior, Ha Viet Tran, Chaiwat Ungsedhapand und 12 weitere

AIDS Research and Human Retroviruses · 2025-01 · 41 (1) · 30-36

DOI: 10.1089/aid.2024.0049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, online erschienen am 10.01.2024. Verfasst von Jessica M Fogel und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Pyridones, DNA, Viral. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated HIV DNA levels in individuals who received long-acting cabotegravir (CAB-LA) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis in the HPTN 083 and 084 trials and had HIV DNA testing performed to help determine HIV status. HIV DNA testing was performed using peripheral blood mononuclear cell (PBMC) samples collected after a reactive HIV test was obtained at a study site. DNA was quantified using droplet digital PCR (lower limit of detection [LLOD]: 4.09 copies/million PBMCs). Final HIV status and the timing of the first HIV-positive visit were determined by an independent adjudication committee based on HIV test results from real-time site testing and retrospective testing at a centralized laboratory. HIV DNA testing was performed for 133 participants [21 HIV-positive (7 CAB-LA arm, 14 TDF/FTC arm) and 112 HIV-negative; 1–6 tests/person]. For persons with HIV, the time between the first HIV-positive visit and collection of the first sample for DNA testing was a median of 81 days for those receiving CAB-LA (range 41–246) and 11 days for those receiving TDF/FTC (range 3–127). Four (57.1%) of the seven CAB-LA cases with infection had a low initial DNA result [three detected

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsPyridonesDNA, ViralPre-Exposure ProphylaxisHumansMaleAdultFemaleLeukocytes, MononuclearViral LoadYoung AdultTenofovirMiddle AgedRetrospective StudiesDiketopiperazines

Stichwörter der Autor:innen

DNAHIVHIV Prevention Trials Networkcabotegravirpre-exposure prophylaxisprevention

Substanzen

Anti-HIV AgentsPyridonesDNA, ViralcabotegravirTenofovirDiketopiperazines

Autor:innen und Institutionen

  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • FHI 360, Durham, North Carolina, USA.
  • The University of North Carolina-Vietnam, Hanoi City, Vietnam.

ORCID-Profile: Jessica M Fogel, Susan H Eshleman

Förderung

  • NIAID NIH HHS

Zitieren

APA

Fogel, J. M., Persaud, D., Piwowar-Manning, E., Richardson, P., Szewczyk, J., Marzinke, M. A., Wang, Z., Guo, X., McCauley, M., Farrior, J., Tran, H. V., Ungsedhapand, C., Mathew, C. A., Mpendo, J., Rinehart, A. R., Rooney, J. F., Cohen, M. S., Hanscom, B., Grinsztejn, B., …, & HPTN 083 and HPTN 084 Study Teams (2025). HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084. AIDS Research and Human Retroviruses, 41(1), 30-36. https://doi.org/10.1089/aid.2024.0049

Vancouver

Fogel JM, Persaud D, Piwowar-Manning E, Richardson P, Szewczyk J, Marzinke MA, et al. HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084. AIDS Research and Human Retroviruses. 2025;41(1):30-36. doi:10.1089/aid.2024.0049

BibTeX
@article{Fogel2025,
  author = {Fogel, Jessica M and Persaud, Deborah and Piwowar-Manning, Estelle and Richardson, Paul and Szewczyk, Joseph and Marzinke, Mark A and Wang, Zhe and Guo, Xu and McCauley, Marybeth and Farrior, Jennifer and Tran, Ha Viet and Ungsedhapand, Chaiwat and Mathew, Carrie-Anne and Mpendo, Juliet and Rinehart, Alex R and Rooney, James F and Cohen, Myron S and Hanscom, Brett and Grinsztejn, Beatriz and Hosseinipour, Mina C and Delany-Moretlwe, Sinead and Landovitz, Raphael J and Eshleman, Susan H and HPTN 083 and HPTN 084 Study Teams, HPTN 083 and HPTN 084 Study Teams},
  title = {HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084},
  journal = {AIDS Research and Human Retroviruses},
  year = {2025},
  volume = {41},
  number = {1},
  pages = {30--36},
  doi = {10.1089/aid.2024.0049}
}
Kostenlos starten →